

# Tanja Kuhlmann

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2478289/publications.pdf>

Version: 2024-02-01

59  
papers

4,845  
citations

147801

31  
h-index

138484

58  
g-index

65  
all docs

65  
docs citations

65  
times ranked

6956  
citing authors

#	ARTICLE	IF	CITATIONS
1	Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. <i>Brain</i> , 2002, 125, 2202-2212.	7.6	650
2	Genetic Correction of a LRRK2 Mutation in Human iPSCs Links Parkinsonian Neurodegeneration to ERK-Dependent Changes in Gene Expression. <i>Cell Stem Cell</i> , 2013, 12, 354-367.	11.1	448
3	An updated histological classification system for multiple sclerosis lesions. <i>Acta Neuropathologica</i> , 2017, 133, 13-24.	7.7	436
4	Integrated single cell analysis of blood and cerebrospinal fluid leukocytes in multiple sclerosis. <i>Nature Communications</i> , 2020, 11, 247.	12.8	242
5	Rapid and efficient generation of oligodendrocytes from human induced pluripotent stem cells using transcription factors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E2243-E2252.	7.1	189
6	Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity?. <i>Acta Neuropathologica</i> , 2012, 123, 627-638.	7.7	176
7	Remyelination in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2003, 206, 181-185.	0.6	175
8	Association between pathological and MRI findings in multiple sclerosis. <i>Lancet Neurology</i> , The, 2019, 18, 198-210.	10.2	163
9	Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E2973-82.	7.1	157
10	BCAS1 expression defines a population of early myelinating oligodendrocytes in multiple sclerosis lesions. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	138
11	VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells. <i>Journal of Experimental Medicine</i> , 2014, 211, 1833-1846.	8.5	134
12	Tissue-resident memory T cells invade the brain parenchyma in multiple sclerosis white matter lesions. <i>Brain</i> , 2020, 143, 1714-1730.	7.6	131
13	CD8+ T-cell pathogenicity in Rasmussen encephalitis elucidated by large-scale T-cell receptor sequencing. <i>Nature Communications</i> , 2016, 7, 11153.	12.8	98
14	Nur77 serves as a molecular brake of the metabolic switch during T cell activation to restrict autoimmunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E8017-E8026.	7.1	93
15	Achievements and obstacles of remyelinating therapies in multiple sclerosis. <i>Nature Reviews Neurology</i> , 2017, 13, 742-754.	10.1	89
16	Late motor decline after accomplished remyelination: Impact for progressive multiple sclerosis. <i>Annals of Neurology</i> , 2012, 71, 227-244.	5.3	88
17	Nogo-A is a Reliable Oligodendroglial Marker in Adult Human and Mouse CNS and in Demyelinated Lesions. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007, 66, 238-246.	1.7	87
18	CD8+ T cell-mediated endotheliopathy is a targetable mechanism of neuro-inflammation in Susac syndrome. <i>Nature Communications</i> , 2019, 10, 5779.	12.8	87

#	ARTICLE	IF	CITATIONS
19	Oligodendrocyte injury in multiple sclerosis: a role for p53. <i>Journal of Neurochemistry</i> , 2003, 85, 635-644.	3.9	85
20	Distinct Neurodegenerative Changes in an Induced Pluripotent Stem Cell Model of Frontotemporal Dementia Linked to Mutant TAU Protein. <i>Stem Cell Reports</i> , 2015, 5, 83-96.	4.8	82
21	In toxic demyelination oligodendroglial cell death occurs early and is FAS independent. <i>Neurobiology of Disease</i> , 2010, 37, 362-369.	4.4	77
22	Astrocyte pathology in a human neural stem cell model of frontotemporal dementia caused by mutant TAU protein. <i>Scientific Reports</i> , 2017, 7, 42991.	3.3	76
23	Lesion stage-dependent causes for impaired remyelination in MS. <i>Acta Neuropathologica</i> , 2020, 140, 359-375.	7.7	69
24	Contrasting potential of nitric oxide and peroxynitrite to mediate oligodendrocyte injury in multiple sclerosis. <i>Glia</i> , 2007, 55, 926-934.	4.9	68
25	Maladaptive cortical hyperactivity upon recovery from experimental autoimmune encephalomyelitis. <i>Nature Neuroscience</i> , 2018, 21, 1392-1403.	14.8	64
26	Nfat/calcineurin signaling promotes oligodendrocyte differentiation and myelination by transcription factor network tuning. <i>Nature Communications</i> , 2018, 9, 899.	12.8	60
27	Extrinsic immune cell-derived, but not intrinsic oligodendroglial factors contribute to oligodendroglial differentiation block in multiple sclerosis. <i>Acta Neuropathologica</i> , 2020, 140, 715-736.	7.7	53
28	The role of glial cells in multiple sclerosis disease progression. <i>Nature Reviews Neurology</i> , 2022, 18, 237-248.	10.1	53
29	Stem cell derived oligodendrocytes to study myelin diseases. <i>Glia</i> , 2020, 68, 705-720.	4.9	46
30	Bcl-2-expressing oligodendrocytes in multiple sclerosis lesions. , 1999, 28, 34-39.		44
31	Stroke induces disease-specific myeloid cells in the brain parenchyma and pia. <i>Nature Communications</i> , 2022, 13, 945.	12.8	40
32	Transcript profiling of different types of multiple sclerosis lesions yields FGF1 as a promoter of remyelination. <i>Acta Neuropathologica Communications</i> , 2014, 2, 168.	5.2	34
33	Multiple sclerosis iPS-derived oligodendroglia conserve their properties to functionally interact with axons and glia in vivo. <i>Science Advances</i> , 2020, 6, .	10.3	29
34	Non-steroidal anti-inflammatory drug indometacin enhances endogenous remyelination. <i>Acta Neuropathologica</i> , 2015, 130, 247-261.	7.7	28
35	TMEM10 Promotes Oligodendrocyte Differentiation and is Expressed by Oligodendrocytes in Human Remyelinating Multiple Sclerosis Plaques. <i>Scientific Reports</i> , 2019, 9, 3606.	3.3	27
36	The farnesoid-X-receptor in myeloid cells controls CNS autoimmunity in an IL-10-dependent fashion. <i>Acta Neuropathologica</i> , 2016, 132, 413-431.	7.7	26

#	ARTICLE	IF	CITATIONS
37	Limited TCF7L2 Expression in MS Lesions. PLoS ONE, 2013, 8, e72822.	2.5	24
38	B7-H1 shapes T-cell-mediated brain endothelial cell dysfunction and regional encephalitogenicity in spontaneous CNS autoimmunity. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E6182-E6191.	7.1	24
39	Interferon $\beta$ -Mediated Protective Functions of Microglia in Central Nervous System Autoimmunity. International Journal of Molecular Sciences, 2019, 20, 190.	4.1	22
40	Single Site Fluorination of the GM <sub>4</sub> Ganglioside Epitope Upregulates Oligodendrocyte Differentiation. ACS Chemical Neuroscience, 2018, 9, 1159-1165.	3.5	21
41	One-step Reprogramming of Human Fibroblasts into Oligodendrocyte-like Cells by SOX10, OLIG2, and NKX6.2. Stem Cell Reports, 2021, 16, 771-783.	4.8	19
42	G-protein-coupled receptor P2Y10 facilitates chemokine-induced CD4 T cell migration through autocrine/paracrine mediators. Nature Communications, 2021, 12, 6798.	12.8	19
43	ALK3 undergoes ligand-independent homodimerization and BMP-induced heterodimerization with ALK2. Free Radical Biology and Medicine, 2018, 129, 127-137.	2.9	17
44	Puma, but not noxa is essential for oligodendroglial cell death. Glia, 2013, 61, 1712-1723.	4.9	16
45	Absence of B Cells in Brainstem and White Matter Lesions Associates With Less Severe Disease and Absence of Oligoclonal Bands in MS. Neurology: Neuroimmunology and Neuroinflammation, 2021, 8, .	6.0	16
46	SKAP2 as a new regulator of oligodendroglial migration and myelin sheath formation. Glia, 2021, 69, 2699-2716.	4.9	16
47	Long-term efficacy of alemtuzumab in polymyositis. Rheumatology, 2015, 54, 560-562.	1.9	14
48	Relapsing-remitting and primary progressive MS have the same cause(s)- the neuropathologist's view: 2. Multiple Sclerosis Journal, 2013, 19, 268-269.	3.0	13
49	Oligodendrocyte myelin glycoprotein as a novel target for pathogenic autoimmunity in the CNS. Acta Neuropathologica Communications, 2020, 8, 207.	5.2	11
50	Interleukin-4 receptor signaling modulates neuronal network activity. Journal of Experimental Medicine, 2022, 219, .	8.5	11
51	Intravenous Iron Carboxymaltose as a Potential Therapeutic in Anemia of Inflammation. PLoS ONE, 2016, 11, e0158599.	2.5	9
52	Activation of FXR pathway does not alter glial cell function. Journal of Neuroinflammation, 2017, 14, 66.	7.2	9
53	The K <sub>2P</sub> channel TASK1 affects Oligodendroglial differentiation but not myelin restoration. Glia, 2019, 67, 870-883.	4.9	7
54	Beneficial contribution of induced pluripotent stem cell progeny to Connexin 47 dynamics during demyelination-remyelination. Glia, 2021, 69, 1094-1109.	4.9	7

#	ARTICLE	IF	CITATIONS
55	Recovery from Toxic-Induced Demyelination Does Not Require the NG2 Proteoglycan. PLoS ONE, 2016, 11, e0163841.	2.5	6
56	XIAP protects oligodendrocytes against cell death <i>in vitro</i> but has no functional role in toxic demyelination. <i>Glia</i> , 2012, 60, 271-280.	4.9	4
57	Tissue donations for multiple sclerosis research: current state and suggestions for improvement. <i>Brain Communications</i> , 2022, 4, fcac094.	3.3	4
58	IL-24 intrinsically regulates Th17 cell pathogenicity in mice. <i>Journal of Experimental Medicine</i> , 2022, 219, .	8.5	4
59	Cover Image, Volume 69, Issue 11. <i>Glia</i> , 2021, 69, C1.	4.9	0